FOLR1 and ovarian serous adenocarcinoma: FRA has been the subject of intense research as a potential therapeutic target in the last several years primarily because of its highly restricted expression profile in normal tissues [40] and high levels expression in a number of cancers of epithelial origin, including serous ovarian cancer [39-52,54-58,68,69].